In spite of affecting the life of millions of people, chronic traumatic brain injury (TBI) has not been hitherto treatable with effective pharmacological tools. This review gives a comprehensive summary of the theoretical data supporting the pharmacological manipulation of the cholinergic system in TBI, pointing out the most urgent targets for further studies. The published clinical evidence of cholinergic treatment in TBI is critically reviewed, with emphasis on modern available cholinergic agents. The lessons from these studies are converted to detailed suggestions for further clinical testing. In addition, the treating clinicians are provided with practical advice, based on personal experience of the cholinergic treatment in over 350 TBI patients. It is concluded that cholinergic agents offer several very promising potentials for the treatment of TBI. However, the final breakthrough requires further well-conducted studies and the potential caveats of the treatment have to be acknowledged.
INTRODUCTION
Traumatic brain injury (TBI) has been called a "silent epidemic". An estimated prevalence of 2.3 % for chronic symptomatic TBI in civilized countries has been presented [1] , although some most accurate epidemiological studies suggest that this may be a clear underestimate [2] [3] [4] . Anyhow, in Northern America and European Union, at least about 20 million citizens have this condition. In population studies, the lifetime prevalence of head injury causing loss of consciousness or amnesia has been from 5.6 to 8.5 % [5, 6] . Taking the developing countries along, TBI has been predicted to become the third important cause for death and permanent disability worldwide [7] . A remarkable feature of TBI epidemiology is that more than half of the victims are children and young adults -a fact that underlines the vast social and economical burden of this condition.
Considering these figures, it is truly astonishing that we are still without a single pharmacological agent that would be officially and internationally accepted for treating chronic TBI. While neuroprotective agents are intensively searched for other conditions too, their largest therapeutic potential would be in preventing chronic TBI. Thus, few other clinical entities offer a more tempting target for the development of effective pharmacological tools.
The reasons for this exceptional situation deserve some discussion. First, and most importantly, in TBI we do not deal with a monotypic disease or standard trauma mechanism, but a highly individual injury without two identical cases. This fact has to be remembered in all treatment efforts of TBI, and solutions which are similar for all or even the great majority of patients are unlikely to be found. Second, the scientific efforts around TBI have suffered from the fact that the treatment responsibility of these patients has traditionally been divided for several specialities, and this situation is unlikely to change in the near future. Indeed, the *Address correspondence to this author at the Department of Neurology, University of Turku, Kiinamyllynkatu 4-8, 20520 Turku, Finland; Tel: +358 2 313 1720; F a x : + 358 2 313 2737; E-mail: olli.tenovuo@tyks.fi clinical problems in acute versus chronic TBI as well as in mild versus severe TBI are in many ways very different, yet their underlying mechanisms have undoubtedly many important common features. Third, the injured brain is often both very sensitive to pharmacological manipulation and unpredictable in its responses, why these patients are not optimal candidates for pharmacological studies and why many clinicians have limited experience of treating these patients with CNS-active drugs.
In spite of the above mentioned problems, there are some common mechanisms which lay in the background of many "classical" TBI-symptoms, and which stem from the biomechanics of TBI. Due to skull and brain anatomy and physiology, some areas of our brains are more vulnerable than others to external forces. Neuroradiological and pathological studies have clearly shown that frontal and temporal areas as well as midbrain structures near the corpus callosum and upper brain stem are most often injured in TBI [8] [9] [10] [11] [12] . Moreover, neuropsychological and clinical studies have shown that the typical syndrome of chronic TBI consists of memory problems, fatigue, attention difficulties, cognitive slowing and behavioral symptoms, especially irritation and emotional lability [13] [14] [15] .
This review discusses the evidence that links the cholinergic system to the pathology and symptoms of TBI. In addition, both published and personal clinical data of cholinergic manipulation in these patients are reviewed. Linking the cholinergic system to brain trauma is by no means a new invention, since the first reports of this association are from sixty years ago [16] .
FUNCTIONAL ANATOMY OF THE CHOLINERGIC SYSTEM
Belonging to the so-called classical neurotransmitters, the distribution of acetylcholine (ACh) in the mammalian brain is fairly well known. The cholinergic system consists of two major centres, which are situated in the basal forebrain (BF) and in the brainstem (Fig. 1) [17] . The cholinergic area of the BF includes ill-defined nuclei, which together form an uninterrupted continuum of cholinergic cells. Due to the morphological appearance of these cells, this system is also called the magnocellular BF. The cholinergic area of the brainstem is situated in the mesopontine tegmentum.
The BF cholinergic system sends widespread projections to the neocortex (Fig. 1) . It is topographically organized so that the anterior part projects to the hippocampus and the posterior portion to the neocortex and amygdala [18] . This innervation is quite strictly unilateral, and despite anatomic proximity, the BF areas of the two hemispheres are connected only by a small group of interneurons [19] . Moreover, this corticopetal innervation from BF does not involve direct feedback from the target areas except from some limbic structures [20] . The extent of the cholinergic BF projections is suggested to be the most significant regulatory system of the cerebral cortex [21] . Indeed, the cholinergic innervation has been shown to be sufficient to maintain cortical activation also in the absence of monoaminergic input [22] , but the interaction with the glutamatergic system is mandatory [23] .
In more detail, the neocortical BF projections terminate both on the pyramidal neurons as well as excitatory and inhibitory interneurons [24, 25] . In both rodents and primates, the pyramidal target cells include at least glutamatergic cortico-cortical and cortico-hippocampal neurons [26] [27] [28] . Functionally, the neocortical cholinergic input from the BF seems to induce long-lasting excitation. The target areas of the corticopetal cholinergic fibres are quite small, why this activation may occur in relatively limited cortical areas, depending on the number of activated fibres [29] .
The hippocampal cholinergic projections from the BF originate from the medial septum and the vertical limb of the diagonal band of Broca. The target cells involve both pyramidal neurons in the hippocampus as well as granule cells in the dentate gyrus and hilar interneurons [30, 31] . Thus, the function of this innervation seems to be in modulating the excitatory input to the hippocampal circuits [32] .
An important target of the cholinergic projections of the BF is the thalamus and especially its reticular nucleus, which receives a very dense cholinergic innervation [33] . Actually the majority of the cholinergic innervation of the thalamus originates from the brain stem cholinergic nuclei, with the exception of the reticular nucleus [34, 35] . On the other hand, 90 % of the brainstem projections to the thalamus are cholinergic [36] . Anatomically, the reticular nucleus is exceptional in covering the whole dorsal thalamus and separating it from the cerebral cortex, thus gating the information through the thalamus. The cholinergic fibres synapse mainly with small thalamic dendrites [37] . The mediodorsal nucleus is another thalamic nucleus receiving significant cholinergic innervation from the BF [38] . This innervation stems not only from the ventral pallidum, but also from the substantia innominata. This thalamic nucleus has been considered to participate in limbic functions through its connections with the prefrontal cortex [39] .
Though the amygdala receives its cholinergic innervation mainly from the substantia innominata, the medial septum can be considered as the other sourse. The BF area innervates cholinergically also the piriform cortex, which lies in close vicinity of the amygdala. The cholinergic innervation in this area seems to modulate the neuronal output to the limbic and brainstem autonomic regions [18] . The BF sends also cholinergic afferents to the olfactory bulb, apparently modulating the incoming olfactory information [40] .
The posterior hypothalamus also receives innervation from the BF, although only a minority of this input is cholinergic [41] . Instead, the more anterior parts of the hypothalamus, especially the suprachiasmatic nucleus, receive more intense cholinergic innervation, which originates both from the substantia innominata, magnocellular basal nucleus and mesopontine tegmentum [42] . In humans, the magnocellular BF includes also the subputaminal nucleus, which is unknown in non-human primates. This cholinergic nucleus projects to inferior frontal areas and is considered to participate in the neural modulation of speech [43] .
ACTIONS OF ACETYLCHOLINE IN THE BRAIN
How does the cholinergic system influence or modulate the brain function ( Table 1) ? The cholinergic neurons of the BF seem to be organized in a specific manner, so that one stimulation modality (e.g. visual input) stimulates ACh release mainly within a specific cortical target area (e.g. visual cortex) [44] . This region specificity for processing sensory or emotional stimuli has been suggested also in human studies [45] . At the cellular level, the cholinergic action is mediated both by nicotinic and muscarinic receptors, whose activation produces disinhibition of intralaminar information flow and inhibition of intracolumnal flow [46] . In practice, this means that the cholinergic innervation seems to modify and fine control the neuronal flow in the cortical networks. This modulation seems to be at least partly under the control of the prefrontal cortex, which is able to affect the cholinergic innervation of other cortical areas both by modulating the BF and by direct cortico-cortical connections [47] . One important function of the cholinergic modulation may be to help the brain to separate significant sensory stimuli -regardless of modality -from the non-significant [48] . In support of these theories, a human fMRI study detected that cholinergic stimulation enhances working Fig. (1) . Major acetylcholine pathways of the human brain.
memory suppressing simultaneously the prefrontal activity, signing apparently increased efficacy of non-frontal working memory circuits [49, 50] .
The relative amount of cholinergic innervation is greater in phylogenetically young parts of the cortex, which may highlight the importance of the cholinergic cortical innervation in humans [18] . This is supported by the fact that the BF is relatively largest in primates, and especially in humans [51, 52] with increasing concentrations of brain ACh from lower to higher organisms [53] . Another interesting feature of the cholinergic system is that ACh seems to function also extra-synaptically, thus producing possibly tonic effects on cortical target areas [54] . The function of this cholinergic modulation seems to be to facilitate other neural mechanisms, promote neurogenesis and induce neuronal plasticity [23, 29, [55] [56] [57] . An important component of this may be the role of ACh in maintaining synaptic plasticity [58] . In rats, the activation of BF has been shown to influence greatly the cortical reorganization [59] , and absence of the cortical input from BF prevents plastic cortical reorganizations [60] [61] [62] [63] [64] . Interestingly, also in spinal cord lesions, the regenerating supernumerary axons have been shown to be cholinergic [65] . Preliminary evidence also from human studies suggests that cholinergic stimulation may be involved in rapid functional plastic changes of the brain [66] .
The effect on plasticity may partly be related to the role of ACh in sleep regulation [67] [68] . In more detail, cholinergic activity during the REM-sleep has been thought to be responsible for the plastic changes required for the consolidation of memory [69] . This view has been supported in human studies, where cholinergic stimulation has increased REM-sleep and stimulated memory functions in healthy, elderly individuals [70] . Acetylcholine may also be neuroprotective, mainly via stimulation of the nicotinic receptor 7 subtype [71] . This same receptor subtype has been shown to be important in postnatal cortical development [72] . There is some evidence that cholinergic stimulation may indeed be neuroprotective also in the diseased human brain [73] . In the developing brain, the cholinergic innervation seems to regulate cellular maturation and cortical differentiation [74] [75] .
In summary, the influence of ACh on cortical function seems to be crucial, both in cortical development, in maintaining the function of the mature brain synapses and in promoting the plastic responses to external stimuli [76] . Although several features presented above link ACh to TBI, the maintenance function in synapses is of special interest, since experimental TBI has been shown to cause an inability to maintain the hippocampal synaptic plasticity [77] . It should be noted that a separate inspection of the cholinergic system is inevitably arbitrary, since in addition to sending widespread cortical projections, the BF is closely linked to an extensive forebrain network or continuum, which contains the medial prefrontal and orbitofrontal cortices, the accumbens shell and extended amygdala and the medial temporal lobe [52, 78] . Moreover, at a biochemical level, the cholinergic system is intimately connected or even colocalized with multiple other neurotransmitters [18] .
CHOLINERGIC NEURONS, COGNITION AND BEHAVIOUR

Attention
The cholinergic system has been shown to influence cognitive and behavioral functions in a variety of ways [79] [80] (Table 2) . Attention is one of the most studied functions and its regulation has been closely linked to the function of the cholinergic system. The BF corticopetal cholinergic neurons influence the activity of the medial prefrontal cortex and an increase in the cholinergic input is essential to accomplish demanding attention tasks [81] . Likewise, cholinergic deficit has produced marked impairment both in sustained and divided attention [82] [83] . Functional imaging has linked the cholinergic system and attention also in humans, with the involvement of the nicotinic receptors [84] [85] .
The regulation of the cholinergic input in attention processes seems to be mediated via prefrontal regulation of amygdala and nucleus accumbens, which in turn send glutamatergic inhibitory input to the BF [86] . A disturbance in this regulation of attention may also explain perseverative behavior, a phenomenon which can be described as an inability to shift attention and which is also linked to cholinergic and prefrontal cortex dysfunction [87] [88] . Vice versa, cholinergic hyperactivity has been linked to the inability to filter sensory stimuli and the occurrence of hallucinations and other schizophrenic symptoms [89] [90] [91] . However, there is strong evidence that also cholinergic hypofunction produces hallucinations [23] . In general, the deficient modulation of incoming sensory information due to cholinergic dysfunction is thought to impair information processing at a more global level [80] , resulting in variable disturbances of awareness and consciousness [23] . 
Sleep
The cholinergic neurons of the BF have been shown to be involved in the rapid-eye movement (REM) associated with dreaming [92] [93] . One theory of dreaming suggests that it is a phenomenon of cortical cholinergic hyperactivity or "hyperattention" [86] . The similarities of dreaming and psychotic states suggest that cholinergic cortical stimulation coupled with the unmodulated action of dopamine may be their common mechanisms [94] . On the other hand, the slowwave sleep associated with consolidation of memory seems to require reduced cholinergic activation [95] [96] . Although the details of sleep regulation are not yet fully understood, it is clear that the BF and brainstem cholinergic systems have an important role in the regulation of sleep cycles, both through their cortical and thalamic projections [23, 67, 97] . The action of ACh on sleep and dreaming seems to be mediated at least partly by the orexin neuronal systems [98] . The role of the ACh system in the apparent uncoupling of prefrontal areas during dreaming [99] has not yet been clarified.
Vigilance
Considering the role of ACh in the regulation of attention and dreaming, it is not surprising that cholinergic mechanisms are important also in the control of vigilance. The reticular formation of the brainstem is known to function as the main center for the control of various sleep-wake states, and this area is connected to the cerebral cortex via BF [93, [100] [101] . Moreover, the cholinergic brainstem nuclei are apparently directly involved in the control of sleep and arousal through their thalamic and pontine connections [79] . As discussed later in this review, fatigue is one of the major symptoms in chronic TBI. Its neurochemical mechanisms are poorly known, but at least an anatomical linkage to the cholinergic system comes from observations that the dorsal prefrontal cortex is involved in the pathogenesis of this symptom [102] and that a disturbance in thalamic-prefrontal connections may be important [103] [104] . The complex background of the regulation of vigilance is apparently closely connected to the cholinergic projections from the BF [18] . The cholinergic system has been linked also to the mechanisms of anesthesia [23] , and the arousal level of the brain to personality traits [84] .
Memory
The role of the cholinergic system in learning and memory seems to be quite complex and has been a subject of debate. A cholinergic deficit caused by BF lesions does not impair learning and consolidation in standard tasks [105] . However, in human life, most learning and memory functions are far more complex requiring intact attention and these processes are affected by a cholinergic deficit [106] [107] . Indeed, memory problems are a well-known adverse effect of anticholinergic medications [108] . Especially the intact function of the septo-hippocampal cholinergic pathway seems to be essential for the formation of new memories [79, 109] . Lesion studies accomplished also in primates suggest that the cholinergic BF system does not have a general influence on learning and memory, but lesion and task-specific influences [27, [110] [111] . Cholinergic neurotransmission has been shown to be essential for the normal function of memory recognition [55] , and to facilitate the long-term potentiation [29] , which is an important step in neuronal plasticity and memory formation. Inhibitors of acetylcholinesterase (AChE) have indeed been shown to stimulate the hippocampal long-term potentiation, apparently via stimulation of nicotinic receptors [112] .
The cholinergic innervation of the amygdala is also involved in the modulation of emotional memory storage [113] . As discussed above, memory and sleep have an apparently strong relationship, and memory problems associated with cholinergic dysfunction may stem from these relationships. However, the accumulated data suggest that some areas of memory may be independent of cholinergic influence [95] . Most interestingly, in healthy humans, cholinergic stimulation enhances cognitive performance in a demanding attention and learning task compared to placebo [114] [115] , as well as in working memory [116] . Regrettably, these studies did not analyze whether the learning effect persisted also after training in the treatment group compared to placebo.
Initiative
A fairly little studied area of brain function is the ability to initiate purposeful action. Other terms describing this same function or its dysfunction are apathy and, in laboratory animals, spontaneous alternation. This action [126, 129] depends on the network containing the BF, limbic areas, hippocampus, thalamus and prefrontal cortex, with connections also to the striatum and cerebellum [117] . As this distribution suggests, cholinergic mechanisms are closely involved. Lesions of the BF have caused deficient spontaneous alternation [118] and testing this function has caused increased ACh release in the prefrontal cortex [119] . There are also several other pieces of evidence linking this action to the cholinergic system [117, 120] , but human studies in this respect are very few [121] .
Behavior
While cognitive processes usually require interactive functioning of various neurotransmitter systems, the behavioral processes are even more complex. Thus, their neurochemical mechanisms are still poorly understood. However, both animal and human studies have shown that cholinergic neurons are involved in many emotional processes. Identification of the emotional significance of a stimulus seems to involve cholinergic activation through a modulating action of the amygdala [122] . The BF may be able to influence emotional states also through its afferents to the interpeduncular nucleus and olfactory bulb [18] .
TRAUMATIC BRAIN INJURY AND THE CHOLI-NERGIC SYSTEM
This review covers the various theoretical and clinical aspects linking the cholinergic system and TBI. In fact, there have been several reviews on this subject during the last fifteen years [141] [142] [143] [144] [145] . However, the rapid progress of neuroscience and the fairly recent clinical experience with cholinergic treatment in human TBI allows us to consider this subject from a better standpoint. Still, much of our knowledge stems from studies in laboratory animals, and we have just recently started to move to human studies with neuropharmacology and functional imaging as the most important tools. When applying the results from animal studies to the human context, one has to take into account the species differences in the cholinergic system [51] [52] as well as the fact that the mechanisms of human TBI are almost always much more complicated than the standard injuries of the laboratory animals [146] [147] . The various alterations in the cholinergic system detected in experimental or human studies are summarized in Table 3 .
Laboratory Animals
At the level of macroscopic anatomy, experimental TBI has been shown to damage nearly all those brain areas that 
Acute phase
Transient massive release of Ach [166, 172] Hypothalamic muscarinic receptor binding [163, 164] Activation of pontine cholinergic neurons [165] Cortical muscarinic receptor affinity [157, [171] [172] Attenuation of cognitive deficits with muscarinic receptor antagonist given pre-injury [175] Attenuation of cognitive deficits with muscarinic receptor agonist given post-injury [176] Loss of ChAT in the basal forebrain, its reversal by muscarinic M1 receptor agonist [177] Loss of ChAT in the hippocampus and temporal cx, and in contused frontal cx [190] [191] Increase in neocortical and hippocampal muscarinic binding sites [179] Synaptosomal choline uptake [187] Long-term changes [192] Reduction in muscarinic M2 receptors [193] [194] Increased sensitivity for muscarinic receptor anta-gonists [196] [197] Impaired response to evoked ACh release [197] [198] [199] Increase of extracellular ACh and attenuation of neurobehavioral deficits by CDP-choline [206] Attenuation of motor and cognitive deficits by AChE inhibitor [207] [208] Loss of BF neurons [221] [222] Reduction in ChAT activity [223] Impaired cholinergically mediated auditory sensory gating [230] [231] ACh = acetylcholine, AChE = acetylcholinesterase, ChAT = choline acetyltransferase, cx = cortex.
are intimately involved in the cholinergic neurotransmission. Hippocampal damage after experimental TBI has been documented most extensively [e.g. [147] [148] [149] [150] [151] [152] . Both the major cholinergic centers of the brain, the BF [153] [154] [155] [156] [157] and the mesopontine tegmentum [158] [159] have also been shown to be affected. In addition, involvement of the thalamus has been detected regularly [e.g. [160] [161] [162] but the data of traumatic experimental neuropathology of the limbic structures, amygdala and nucleus accumbens, are practically non-existing.
The cholinergic system has been considered to be involved in the pathophysiology of traumatic unconsciousness already in the early 1980's, when concussed rats showed a transient initial increase in muscarinic receptor binding in the hypothalamus but not in the other brain areas studied [163] [164] . However, later unconsciousness has been linked to brain stem dysfunction, and a study in cats suggested that the mechanism may be related to the activation of cholinergic pontine neurons [165] . This was supported by a study that reported increased cholinergic activity in the dorsal tegmentum immediately after the injury [166] . This increased cholinergic turnover was blocked by scopolamine pre-treatment [167] , and pre-treatment with anticholinergic agents reduced also the post-traumatic behavioral changes [168] . Indeed, it has been suggested that anticholinergic therapy might be beneficial in a brain-injured patient [141, 169] , and a cholinergic hyperactivity was considered to be a candidate mechanism for TBI-induced neuronal damage [170] .
An initial massive ACh release after injury has not yet been convincingly shown in humans, but animal studies have suggested its occurrence, causing an initial down-regulation of muscarinic receptor affinity [157, [171] [172] . In one study, diminished noradrenergic activity accompanied the immediate cholinergic hyperactivity following trauma-induced unconsciousness [173] . The role of ACh in the posttraumatic unconsciousness was supported also by a study, which suggested that the arousing effect of thyrotropin releasing hormone was mediated by the nicotinic receptors [174] . Treatment with muscarinic receptor antagonist scopolamine before a fluid percussion injury in rats attenuated the following cognitive deficits, while the same treatment given after the injury was ineffective [175] . This too was interpreted to suggest that the cognitive defects are caused by a brief cholinergic hyperactivity immediately after trauma.
Concerning the cholinergic receptor function, muscarinic receptor stimulation was effective in attenuating the posttraumatic cognitive impairment when started 24 hrs after the injury, but not when started after two weeks [176] . Later studies of the same authors showed that the trauma-induced loss of ChAT activity in the BF could be reversed by muscarinic M1 receptor agonist, suggesting that the trauma does not necessarily cause neuronal loss in the BF and that the cholinergic deficit may be reversible [177] . This same receptor agonist was also shown to improve cognitive performance after experimental TBI [178] . In one study the increased number of muscarinic receptor binding sites in the hippocampus and neocortex persisted at least for two weeks after an injury, but the binding was unchanged in scopolamine pre-treated rats and sham-operated controls [179] . The two muscarinic receptor subtypes, M1 and M2, have shown different alterations shortly after the injury, with the M1 binding being unchanged [180] . On the other hand, in another study, alterations especially in the M1 receptors were associated with the long-term behavioral changes [168] .
In a study comparing the eventual post-traumatic changes in different cholinergic receptor subtypes in the hippocampus, the most marked and consistent change was a reduction in the 7 nicotinic receptors, while changes in other nicotinic and muscarinic receptors were both more restricted and of lower magnitude [181] [182] . Moreover, nicotine treatment attenuated the deficits in the 7 nicotinic receptors, thereby improving cognitive performance [183] [184] .
Altogether the above studies have suggested that the excessive cholinergic flow produces an initial downregulation of muscarinic receptor affinity and a subsequent increase in binding sites, as a reactive attempt to normalize the cholinergic hypofunction. The reduction in the number of nicotinic receptors may be a consequence of presynaptic neuronal loss, as the nicotinic receptors are predominantly presynaptic [185] . Consequently, the magnitude of the initial cholinergic storm could well correlate with the severity of the injury on the BF neurons. This raises several intriguing applications to the human TBI, as discussed later in this review.
An important study [153] showed that a fluid percussion injury produces a bilateral loss of cholinergic BF neurons depending on the site of impact, without neuronal loss in the pontine cholinergic neurons or in the dopaminergic and noradrenergic innervation. After the same fluid percussion injury model, rats showed a marked cell loss of the cholinergic neurons in the medial septum, which was greatly prevented by post-injury infusion of nerve growth factor [156] . A very similar result was obtained in a cortical impact model, where the authors showed that the cognitive deficits were cholinergically mediated but the motor deficits were not [186] . Concerning the extent of cholinergic dysfunction after an injury, also more recent studies have shown that the effect is not limited to local or ipsilateral neurons, but also to the contralateral side after a slight delay [157] .
In a study with rats, the cholinergic neurons of the medial septum and nucleus of the diagonal band of Broca showed a marked but transient loss after fluid-percussion injury [154] . Similarly suggesting transient phenomena, another study [187] noted a significant impairment in learning and synaptosomal choline uptake up to one week after injury with a subsequent recovery before three weeks post-injury. Most animal studies have used either fluid percussion or controlled cortical impact as a trauma model. Interestingly, in a study using impact acceleration injury, the rats showed similar cognitive deficits as in the other injury models, but without a correlation to the cholinergic function as measured with synaptosomal choline uptake from the hippocampus and parietal and entorhinal cortices [188] . In this same injury model, the aged rats showed a much more impaired recovery than young rats, but differences in choline uptake were modest suggesting that the age-related difference is not readily explained with an age-related cholinergic decline [189] .
The enzyme synthesizing ACh, the choline acetyltransferase (ChAT), has shown reduced activity both in the hippocampus and temporal cortex already one hour after a fluid percussion injury [190] . Likewise, frontal contusion produced a profound decrease in the cortical ChAT, which however, largely recovered within 2-3 weeks [191] . After cortical impact injury, rats showed a marked increase in the amount of vesicular ACh transporter but a significant decrease in the muscarinic receptor subtype 2 immunoreactivity, lasting for one year after the injury [192] [193] [194] . This was interpreted to suggest a compensatory response in order to increase the deficient cholinergic transmission. An earlier study already showed that the cholinergic dysfunction after injury is not caused by decreased availability of choline for the synthesis of ACh but by either deficient uptake of choline or loss of cholinergic neurons [195] .
A very interesting experimental study [196] showed that rats were sensitive to muscarinic receptor antagonist scopolamine both after moderate cortical injury and mild concussive impact compared to sham-injured controls, even though the group with mild concussion performed otherwise normally. This suggests that even with apparently normal function, covert deficits of the cholinergic system may persist, manifesting themselves only during special challenge. In their later work, the same authors showed that these covert deficits can persist long after the initial symptomatic period and that the recovery rate depends on the magnitude of the injury [197] . Moreover, after cortical impact, the cholinergic systems ability to respond to an evoked release of ACh has been shown to be chronically impaired both in the neocortex and hippocampus [197] [198] [199] .
An important aspect concerning the post-traumatic events is the time-schedule of the eventual changes. This is of primary importance when considering the available or best time-window for therapeutic interventions. Recent studies have confirmed that axonal injuries are not momentary but instead processes which may last from days to months [200] [201] . The role of the cholinergic circuits in these processes has not yet been defined, but in rats, the trauma-induced disruption of the cholinergic septohippocampal pathway has been shown to be a process lasting at least 10 days after the injury [155] .
The role of ACh in experimental TBI does not seem to be restricted to neuronal modulation. When studying the changes of cerebral blood flow after TBI, an initial decrease and subsequent increase in cerebral blood flow was seen [202] . The spontaneous recovery was blocked by muscarinic receptor antagonist scopolamine, while the AChE-inhibitor physostigmine reversed the initial decrease partially near the injury and totally in more distant areas. The diffused tonic action of ACh has been considered to regulate also the brain vasculature [203] . A strong support for the role of ACh in TBI comes also from the observation that transgenic mice overexpressing AChE (having thus reduced cholinergic function) showed delayed recovery and increased hippocampal cell loss after closed head injury [204] .
In the above mentioned experimental studies, the cholinergic system has been manipulated with diverse pharmacological agents. To bring the experimental data closer to human applications, there are animal studies from the previous years which have used the modern available cholinergic agents. The study with the first commercial AChE-inhibitor, tetrahydroaminoacridine, was disappointing, since a two-week intraperitoneal administration starting at 24 hrs after the injury resulted in impaired cognitive performance compared to controls [205] . On the other hand, CDP-choline both increased extracellular ACh levels and attenuated the post-traumatic neurobehavioral deficits administered with a similar time-frame as in the former study [206] . Another AChE-inhibitor, rivastigmine, reduced the trauma-induced cerebral oedema and ameliorated the motor and cognitive deficits for at least two weeks when given as a single injection immediately after a severe TBI in mice [207] [208] . Moreover, this neuroprotective effect was abolished by mecamylamine but not by scopolamine, which suggested that the beneficial effect was mediated mainly via the cholinergic stimulation of nicotinic receptors. Most interestingly, this same substance has prevented delayed hippocampal neuronal death after ischemic damage [209] and decreased the amount infarcted tissue after middle cerebral artery occlusion [210] .
Human Studies
Despite the marked differences in the anatomy of the cholinergic system between man and rodents, the central role of the BF cholinergic system also in human cognition is widely accepted. Selective injuries of the BF region in humans are rare, but have been described e.g. in patients with aneurysms of the anterior communicating artery. These patients have exhibited marked problems in memory and executive functions [80, [211] [212] . In Alzheimer's disease (AD), a cholinergic deficit of the BF has been considered as a major contributor to the cognitive deficits of the disease [213] [214] . Also, the cognitive decline in aging has been linked to decreasing cholinergic innervation from the BF [215] .
As discussed earlier, the medial temporal lobe involving the hippocampus is intimately involved in the cholinergic neuronal circuits. Several studies have shown this area to be especially vulnerable also in human TBI [216] [217] [218] [219] [220] . An important support for the cholinergic theory in human TBI has evolved from observations of BF pathology both in living humans [221] and post-mortem after fatal head injury [222] . This later study showed signs of BF pathology both from tissue distortion and secondary ischemic damage.
A post-mortem neurochemical study involving 16 brains from fatally head-injured victims found that the presynaptic cholinergic marker ChAT was markedly reduced while the nicotinic binding was unchanged as compared to controls [223] . The reduction in ChAT was more marked with prolonged survival. The correlation between ChAT and synaptophysin levels was interpreted to result in loss of presynaptic cholinergic terminals. This result supported thus an earlier observation of reduced ChAT activity but preserved M1 and M2 muscarinic receptor binding in a smaller post-mortem material [224] .
Evidence of a cholinergic deficit of attention has been also obtained in human TBI. Auditory sensory gating has been shown to be mediated by cholinergic innervation both in humans and laboratory animals [225] [226] [227] [228] [229] . Impaired auditory sensory gating was detected in all patients after TBI of variable severity suffering from attention difficulties [230] . In their later study, these authors noted that the impaired sensory gating was accompanied with hippocampal volume loss even in "mildly" injured persons [231] . A recent study also suggested that the postconcussion syndrome after mild TBI results from deficient control of incoming sensory information [232] .
In rats, lesion of the BF cholinergic neurons caused a transient increase of cortical glucose metabolism [233] , and very interestingly, an initial hyperglycolysis has been detected with PET also after human TBI [234] . Whether this phenomenon in humans is caused by cholinergic mechanism is not known.
CHOLINERGIC TREATMENT OF TRAUMATIC BRAIN INJURY -SUMMARY OF EVIDENCE
Studies Without Acetylcholinesterase Inhibitors
Maybe surprisingly, the history of cholinergic treatment of TBI is more than fifty years old [235] [236] . Thereafter, various cholinergic agents have been tested in this indication in about twenty published works, whose protocol has varied from case studies to randomized controlled trials. A thorough analysis of the published studies was done a couple of years ago [144] . As that review covered in detail all reports concerning cholinergic agents before the era of modern AChE-inhibitors, these will not be discussed here. In summary, these included ten studies accomplished between the years 1982 -2000, containing altogether 299 patients. The agents used were physostigmine, lecithin and CDPcholine (citicholine). In all studies some kind of benefit was reported, usually in memory (7 studies), attention (4 studies), or verbal function (4 studies). In addition, benefits in arousal, orientation, post-concussion symptoms and behavior were noted in some studies. Many of these studies were covered also in two earlier reviews [237] [238] .
Studies with Acetylcholinesterase Inhibitors
Most of the above-mentioned earlier works have only theoretical interest, since seven of these used physostigmine, which has problematic vascular and autonomic adverse effects and is therefore not in clinical use. The cholinergic drug therapy has moved to a new era with the use of AChEinhibitors. The first of these, tetrahydroaminoacridine (tacrine), has largely disappeared from clinical use because of gastrointestinal adverse effects. Instead, donepezil, galantamine and rivastigmine are widely used as a treatment for AD and later also for other forms of dementia, like vascular, Lewy-body, frontotemporal and Parkinson's dementia [239] [240] [241] [242] . In recent years, there are also reports of beneficial effects in patients with multiple sclerosis [243] [244] [245] , autism [246] , Korsakoff syndrome [247] , schizoaffective disorder [248] , amnesia due to subarachnoid hemorrhage [249] , amnesia due to psychotropic drug use [250] and attention deficit hyperactivity disorder [251] [see 252 for review]. In these reports, AChE-inhibitors have shown a wide variety of cognitive benefits, mainly in memory, attention and verbal functions.
Hitherto, there are 14 published reports of AChEinhibitors in TBI. These are summarized in the Table 4 .
In general, RCTs are considered nowadays essential to prove the eventual efficacy of a drug treatment. The two reported RCTs include 175 patients, eighteen on donepezil and 157 on rivastigmine. What do these two studies tell us? First, the main criticism of the smaller study [259] concerns two issues: the small number of patients and the inclusion of both subacute and chronic patients, with the former having expectedly also spontaneous recovery during the study. Although the authors discussed that the crossover study design and the results suggested that this factor did not seem to influence the results, it seems very difficult to rule out the confounding effect of spontaneous recovery in some patients for the group statistics. Another shortcoming of that study is the limited battery of outcome measures, including only two indexes of short-term memory (Auditory and Visual Immediate Indexes from the Wechsler Memory Scale III) and one index of sustained attention (Paced Auditory Serial Addition Test). Last, this study used a crossover design, but the authors did not report whether the patients remained truly blinded (i.e. did they guess the treatment sequence), which may well be questioned when using this kind of medication causing probably both adverse and positive subjective effects.
The later RCT with rivastigmine [265] did not use crossover design and had a clearly larger material. A major shortcoming of the reported study is also the limited test battery, consisting only of a memory index (Hopkins Verbal Learning Test) and an attention test (Cambridge Neuropsychological Test Automated Battery CANTAB, Rapid Visual Information Processing subtest). Other eventual shortcomings are hard to evaluate, since the original study still awaits its publication. However, these were all chronic stable patients with persistent cognitive deficits due to a clinically definite TBI.
It is noteworthy that the small study with only 18 patients showed significant differences compared to placebo in all outcome measures, while the larger one failed to show any significant differences. It is unlikely that this difference would be caused by the agent used, since clinical efficacy does not seem to be different [266] . A likely explanation comes from the study design and patient selection, and the discrepancy between the results in these two studies further suggests that including subacute patients in the smaller study may have influenced the results. A third possible explanation is that the outcome measures used in the smaller study were much more sensitive to TBI-related change, but this seems unlikely.
Summarizing the existing documentation of AChEinhibitors in the treatment of TBI, the available data suffer from paucity of sufficient RCTs and from the very variable patient selection and outcome measurement. All published articles have reported some kind of benefit, usually in global functioning, memory or attention, which would be in compliance with the theoretical knowledge of enhanced ACh function. However, it is very much possible that a publication bias exists, due to which negative results have remained unreported. On the other hand, it may be that similar positive experiences have not been reported, either. As a critical conclusion from the published studies, we do not have yet evidence that AChE-inhibitors would benefit TBI patients in general. However, there are strong indications that some TBI patients do benefit markedly from the treatment [e.g. 257, 261, 264, 266] . How to find these patients will be discussed in the following chapters.
CHOLINERGIC TREATMENT OF TRAUMATIC BRAIN INJURY -PRACTICAL ISSUES
The author has hitherto treated more than 350 TBI patients with AChE-inhibitors during the last five years, and this chapter is meant to offer this experience to a reader interested in trying these drugs in clinical practice. The experience includes the published 111 patients [266] and a submitted but yet unpublished RCT with rivastigmine in 101 patients, the rest being outpatients in normal clinical practice after the publication of the clinical report.
Patient Selection
How to know which patients should be treated with AChE-inhibitors and which ones are unlikely to benefit? The published studies and the clinical experience give fairly little evidence to answer. The subanalysis of the larger published RCT suggested that those patients who have more memory problems respond better [265] . On the other hand, clinical experience suggests that subjective improvement of memory in responders is at the most modest. This paradox may hide some sense. The more profound involvement of memory 
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Case series C, all severities > 6 months Marked or excellent subjective benefit in 55 % [266] functions may be a sign of a co-existing significant cholinergic deficit, although cholinergic stimulation does not directly enhance memory functions. Indeed, the theoretical basis reviewed earlier suggests that ACh has a modulating role in memory functions but not a direct effect.
Does 'more memory problems' mean a more severe TBI? Statistically yes, but at an individual level, this connection is much more obscure. As discussed several times earlier, the definition of TBI severity is extremely complex [e.g. [267] [268] [269] [270] . Level of consciousness and duration of post-traumatic amnesia (PTA), which mainly have been used as severity indexes, describe various yet accurately undefined aspects of brain injury, and both have shown only moderate predictive value [271] [272] [273] [274] [275] . Many published reports ( Table 4) have included only or mainly severely injured patients, so we may quite firmly conclude that at least the severely injured patients may benefit from AChE-inhibitors. However, none of the published reports have suggested that mildly injured patients would not respond. Consequently, this far we can only say that patients with marked cognitive deficits may benefit, regardless of the initial trauma severity.
So far also the other background variables such as age, gender, trauma mechanism or time since injury have failed, to emerge as significant predictors of treatment response. Theoretically, it could be thought that older persons would more probably benefit because of age-related cholinergic hypofunction, regardless of trauma. Interestingly, many TBI patients describe as if they had suffered a sudden aging of several years because of the injury. Although aging of the brain has been suggested to be a process of cholinergic denervation [215, 276] , the clinical experience does not suggest that older people with TBI are more prone to benefit. On the other hand, it could be thought that the plasticity enhancing effect would be more significant in younger victims. Indeed, many of the most impressive responses have occurred in young patients.
The question about the trauma mechanism as a predictor is most intriguing. As known, the exact mechanism of brain injury is extremely hard to evaluate, since the details of the impact are usually unknown, the brain imaging only vaguely reflects the extent and distribution of neuronal injury [277] , and since many poorly documented secondary injuries are common especially in the severely injured patients [278] [279] [280] . However, at least in theory, the responders are likely to have a presynaptic cholinergic deficit. Increasing the cholinergic tone is unlikely to work if the postsynaptic network is not functional. Thus, the responders have probably a lesion in the ascending cholinergic system from the BF or brainstem or both. It would be logical that patients having these dysfunctions have some common features either in trauma mechanism or spectrum of symptoms, or both. This area will be discussed further in the following chapter.
Whether the timing of the cholinergic stimulation after injury is critical is also a most interesting topic. This far, most studies have included only chronic stable patients, which is natural since separating the drug effect from spontaneous recovery would normally be impossible, considering also the unpredictable profile of recovery after TBI. Once in chronic stage, the accumulated evidence does not suggest that it would be of significance whether it is one year or ten years from the injury. Several excellent responses have been seen in patients whose trauma is far over ten years old. Treatment in the acute or subacute phase is discussed later in this review.
Selecting the Drug
At present we have three different AChE-inhibitors available -donepezil, galantamine and rivastigmine. Although they all share as main mechanism the inhibition of the AChE, they also have differences (Table 5) , which may be significant, at least in individual patients. Are some of these agents more efficient in TBI than others? So far, we have very modest documentation from galantamine, and clearly more but insufficiently from both donepezil and rivastigmine. The only report using all of these did not detect any significant difference in the clinical response [266] . However, as stated in that report, at an individual level, there may be surprisingly large differences between these three agents both in effect and tolerability. This is not surprising, since the individuality of TBI may make even slight neurochemical differences significant. Thus, ideally the best alternative should be sought individually. The unpredictability has appeared in clinical practice so that some patients who do not respond at all to one AChE-inhibitor may get an excellent response from another alternative. However, more commonly the combined profile of efficacy and adverse effects is the determining factor. In that regard, galantamine [266] .
Dosing
How to give the treatment in practice? A common principle in TBI medication is "start low, go slow" [281] , and this concerns also the treatment with AChE-inhibitors. The recommended initial dose is 5 mg for donepezil, 4 mg for galantamine and 1.5 mg for rivastigmine, given in the morning after sufficient breakfast. This initial dose should be continued for at least one week, and if adverse effects occur or the patient is generally sensitive to centrally acting drugs, then the dose can be prolonged for two to four weeks. Another reason to start low is that fairly many patients get a clear response already from this initial dose and some of them do not tolerate higher doses. After the initial dose, donepezil may be added to 10 mg o.d., galantamine to 4 mg b.i.d. and rivastigmine to 1.5 mg b.i.d. The second daily dose of galantamine and rivastigmine should be taken sufficiently early during the day, preferably between 0 and 3 p.m., since later dosing causes often sleep problems. Indeed, some treatment failures are due to weakened sleep quality. It should be also remembered that cholinergic down regulation seems to be an important feature of memory consolidation during slow-wave sleep, and cholinergic hyperactivity at night may disturb this process [96] . The best time for second dosing should ideally be sought individually, and some patients indeed can tolerate only one daily dose in the morning.
Donepezil has much longer half-life (about 70 hrs) than the two other compounds (< 10 hrs), and sleeping problems may sometimes be avoided by changing from donepezil to galantamine or rivastigmine. Otherwise, pharmacokinetic properties are hard to connect to clinical response, since the effect is obviously determined by receptor alterations that follow from AChE-inhibition, and not by the enzyme inhibition itself. This is reflected in that the clinical effect usually vanishes first after two to three weeks after stopping the medication, if it has been in use for several weeks or longer. If the patient seems to get benefit and adverse effects do not occur, dose escalation of the recommended maximum may be tried. However, in some patients a higher dose gives worse response even without adverse effects, which is logical since cholinergic hyperactivity may disturb attention through increased detection of irrelevant stimuli [89, 282] .
Clinical Response
An interesting feature of the cholinergic treatment in TBI is the very rapid response. Once the efficient dose has been found, the response occurs usually immediately. Indeed, some patients have chosen to use the medication only when required and not on a daily basis. This observation suggests that the treatment response is mediated via nicotinic receptors [185] . As many patients experience the response in low doses, these two features make these drugs very easy to test for the clinician and for the patient.
According to clinical experience based on both clinical case analysis and RCT, about half of the patients do respond. This percentage may well depend on patient selection, and is based on material with all TBI severities and with patients with variable cognitive impairment varying from mild (normally at work) to severe. Probably the figure could be higher in more severely injured and lower in only mildly symptomatic patients. From those who do not gain benefit, about one half do not respond and the other half cannot use the medication due to adverse effects. As stated above, waiting for an eventual response is not necessary if tolerability is not causing problems.
How does the treatment response occur? In clinical practice, by far the most reported benefit is increased vigilance. The devastating fatigue of TBI diminishes or sometimes disappears, which causes an often remarkable improvement in daily functioning. Most of these patients report also improved attention and increased initiative ability. To what degree are these consequences of improved vigilance is unclear, since it is self-evident that fatigue has large influence on both sustained attention and general activity. In fact, the results of the published studies suggest that improved attention may well be a secondary phenomenon, since many patients have shown subjective and objective general improvement, but the larger RCT tests of attention did not reveal significant changes [265] . Most TBI patients are able to function fairly well during limited periods, but the problems occur when trying to cope for longer periods e.g. at work. Likewise, changes in subjective memory reported by some patients may well be consequences of improved attention, since selective attention is a prerequisite for proper memory function. Similarly, improvements in mood and diminished irritability reported by many patients may well have the same background of increased vigilance. In general, the patients responding to AChE-inhibitors often describe as if they were again feeling somehow normal. This type of response described above is well in accordance with theoretical background that ACh maintains cortical activation and synaptic function, thus increasing capability and general functioning of the brain, like a new battery brightening the light of a dim torch. While the rapid response suggests the involvement of the nicotinic receptors, it is extremely interesting that recent results suggest that the nonsynaptic nicotinic receptors influence the activity of neural networks in key structures of the brain [283] . These theoretical results would thus very nicely be fit for the observed clinical pattern.
Cautionary Notes
A certain degree of caution has to be kept in mind when treating an injured brain with a pharmacological agent. This is especially important in TBI, where every patient has a unique injury, and may thus manifest a unique reaction to pharmacological manipulation. Generally, the adverse effects are very similar as usually with there agents nausea, diarrhea, insomnia and headache being common. Potentially, the most problematic adverse reactions include disorders of behavior such as confusion, psychosis and hallucinations. While in some patients, AChE-inhibitors may be the drug of choice for these symptoms [264, own experience], they may appear in patients not formerly having such problems. Therefore, if the psychic or cognitive state of the patient seems to worsen when starting these agents, the medication should be discontinued immediately. However, such a reaction does not necessarily mean that another AChE-inhibitor causes similar problems, but naturally extra caution should be followed. In general, the patients should be informed to contact immediately if something other than common initial adverse reactions occur.
Another notable issue when using AChE-inhibitors in TBI is the potential for central interactions with other centrally acting drugs. Brain injured patients may react unpredictably and paradoxically to all CNS-active agents. Thus, adding centrally acting agent to another may cause interactions in brain networks manifesting themselves as unpredictable adverse effects. Therefore, optimally other CNS-active drugs should not be in use or at least their dose has to be kept stable when testing AChE-inhibitors. So far, no special family of drugs has been more problematic in this respect than others, but with increasing experience, not recommendable combinations may well emerge. On the other hand, this same phenomenon also offers some possibilities, since biochemical alterations after TBI are surely multiple. So far, combination treatments have to be planned on a highly individual basis with strong indications, but theoretically and in some patients also in practice, combining AChE-inhibitor to NMDA-receptor antagonist memantine may be advantageous.
Duration of Treatment
If the patient responds, for how long should the treatment be continued? If we consider AChE-inhibitor treatment as a restitution therapy for cholinergic deficiency, like insulin for diabetes, then we would answer, 'for the rest of life'. This may well indeed be the case in the majority of patients, although we still have experience only for a limited number of years of treatment. However, the most interesting clinical observation is that in some patients, the treatment response seems to continue after a few months medication despite stopping the treatment. This was supported also in the first RCT showing a carry-over effect [259] . Considering the actions of ACh in the brain reviewed above, it is conceivable that cholinergic stimulation may cause plastic changes that may themselves be able to normalize or maintain normal brain function. If this mechanism can be proven in further studies, it may open a whole new era for neurological rehabilitation. In practice, it is wise to continue the treatment of responders from 3 to 6 months, after which a wash-out may be proved. This may be done either by gradual decrease or sudden stopping. In those who do not maintain the response, the symptoms reappear usually within two-three weeks. The response for re-treatment has been similar than for initial treatment, and the longest follow-ups of some years have not demonstrated any clear wearing off this far.
FUTURE PROSPECTS FOR THEORETICAL RESEARCH
The study of TBI offers an excellent possibility to combine clinical research to the basic research of brain function, all the way from molecular and cellular events to generation of higher brain functions. The accumulated data of cholinergic function and TBI raises several highly interesting issues for the target of further studies. The following paragraphs provide some examples.
Addiction
The study of addiction is one of the hot targets in modern neuroscience, for good reasons that we all know. The cholinergic system is closely involved in reward mechanisms and addiction (c.f. action of nicotine on nicotinic receptors), and cholinergic hyperactivity is connected with addiction [284] [285] . This raises several questions concerning the connections between TBI and addiction. Because alcohol and drug abuse are important risk factors for TBI [286] [287] , do these patients have different recovery from non-addicts? If so, are the cholinergic mechanisms involved? A clinical impression is that chronic alcoholics and drug addicts tolerate surprisingly well repeated brain traumas. Although this has been questioned [286] , several works suggest that alcohol use is not associated with increased risk of unfavorable recovery [288] [289] [290] [291] [292] , which seems surprising. Could increased cholinergic tone have some protective effect? Why many alcohol addicts can totally stop drinking after TBI and many TBI patients report diminished alcohol tolerance [293] ? Could these changes appear because the deficient cholinergic response does not produce reward mechanisms anymore? If so, do these patients have some common lesions or other common features? To go further in these speculations: could these studies reveal some brain area where manipulation (pharmacological or neurosurgical) could be used to treat addiction?
Apolipoprotein E
The role of apolipoprotein E (ApoE) in the recovery from CNS lesions has been a subject of intensive studies. The early results of increased risk for unfavorable recovery in carriers of the 4-genotype [294] [295] have not been fully supported in later larger studies. A recent follow-up study with 396 TBI subjects for a mean 18 years showed deterioration in one third of patients, but this did not seem to be significantly correlated to the ApoE [296] . A study of head-injured veterans of war suggested that memory functions are influenced by ApoE, while executive functions are not [297] . A large follow-up study with over 1000 TBIpatients found that the ApoE4 was not in general associated with poor outcome, but that it interacted with age, having deleterious effect on recovery in younger patients [298] . These observations become even more interesting due to the report that the ApoE is especially selective for the cholinergic cells of the BF, and this selectivity is variable also within different parts of the BF [299] . Deficiently functioning ApoE impaires the cholinergic reinnervation in the hippocampus [300] [301] . Thus, are the ApoE 4 positive patients at special risk only if their BF gets injured and if some synaptic hippocampal maturation is still in progress?
ApoE has been shown to be expressed as long as six months after the TBI [302] . If cholinergic function maintains the synaptic plasticity [58] , do the occasional patients with deteriorating symptoms after a seemingly mild injury have a combination of BF injury and ApoE 4, causing a slowly progressing diffuse axonal injury, thus serving as an explanation for the so-called miserable minority [303] ?
Brain Maturation and Aging
Studies suggest that the role of ACh in the brain depends on the maturity of the CNS. In the developing CNS, a cholinergic deficit seems to have a greater influence than in the mature brain [74, [304] [305] [306] . Moreover, in the immature brain, the influence depends on the age of the individual [74] . Does this apply also to humans -is the prognosis of children's TBI dependent on the age of the child? Does cholinergic injury in different phases of brain maturation produce different consequences? If the cholinergic system develops deficiently due to a TBI before adulthood, does it cause hastening of the aging phenomena of the brain? Does the association between TBI and AD stem from earlier manifestation of the disease in patients with cholinergic hypofunction, rather than from a causal relationship [307] [308] ? Alzheimer's disease has been proposed as a phylogenetic disease [309] -does the phylogenetic difference in the cholinergic system [310] make human brains susceptible to injuries or diseases which are unknown or rare in lower animals? From evolutionary viewpoint, if an animal would have similar consequences from TBI as humans -poor attention, slowness of reactions, impaired learning -it would hardly survive. Are the phylogenetically newest parts of the brain also the most susceptible for TBI?
Cholinergic Mechanisms of Brain Trauma
The exact consequences of TBI on the human cholinergic system should be studied, especially since the results from the laboratory animals do not necessarily apply to humans due to species differences discussed above. The mechanism of traumatic unconsciousness is still unknown. Is the loss of consciousness caused by a dysfunction of the ascending cholinergic system from the brainstem [23] ? Is the posttraumatic amnesia an acute cholinergic dysfunction of the BF [179] ? This would quite nicely explain why the duration of PTA seems to be so important for the prognosis of cognitive recovery [311] . The period of amnesia after acute TBI could well be a clinical representation of the initial cholinergic dysfunction, as signs of cortical (especially prefrontal) and hippocampal dysfunctions are typical for this period [312] . Indeed, the duration of PTA has been in many studies a better predictor of the cognitive sequels than loss of consciousness. The "concussional" loss of consciousness has been regarded as a sign of brainstem dysfunction [313] , and thus it would be understandable that a transient or shortlasting loss of consciousness does not necessarily mean a permanent cortical dysfunction. Indeed, in minor injuries, the presence of loss of consciousness has not predicted subsequent memory problems [314] .
How does the cholinergic deficit differ between diffuse and focal injuries [188] ? In TBI, connecting cognitive deficits to either focal or diffuse lesions is often impossible [315] , but a neurochemical perspective for symptom generation could be more relevant. Many of the neuropsychological deficits after TBI are caused by prefrontal dysfunction [316] -is the impaired cholinergic regulation of the prefrontal cortex crucial for several chronic TBI symptoms? Do humans also have the cholinergic "storm" in the hyperacute stage of TBI? If so, is this storm a consequence reflecting the magnitude of BF injury, or does this storm cause damage in the receptors and synaptic terminals of the ascending tracts? Behaviour of the nicotinic receptors (studied e.g. with 11 C-nicotine PET) during traumatic unconsciousness and after regaining consciousness would be most interesting. These basic data could clarify many mysteries concerning the mechanisms and prognosis of TBI and open new ways for neuroprotective actions.
Genetics, Demographic Variables and Brain Trauma
As shown earlier in this review, it is apparent that only a portion of TBI patients respond positively to cholinergic enhancement. Clarifying the mechanisms behind such differences would be very important. Are the cholinergic systems basically different in different individuals? Could this be one explanation for the unpredictable recovery in TBI? Genetic polymorphism has not only been detected in the repair processes such as ApoE, but also in the function of the choline transporter [317] . Does this polymorphism have some prognostic role? The various cholinergic systems have been shown to be variably sensitive for excitotoxic injury [318] -is this selective sensitivity behind some of the common TBI consequences? Is the selective post-traumatic loss of the various parts of the hippocampus [218] connected with cholinergic dysfunction?
Several studies have suggested that the prognosis of TBI is different between the sexes [319] . Basic research suggests that estrogen affects the cholinergic system [74, 320] -could this influence the differences in prognosis between the sexes? Does those patients who do not respond to cholinergic treatment or who even show paradoxical responses, have some other transmitter systems mainly involved -e.g. the noradrenergic system [321] [322] ? Do differences in the cholinergic receptor system [185] determine the therapeutic response and influence the symptom profile? What kind of pharmacogenetic and pharmacogenomic factors possibly determine the treatment response in TBI patients [323] ? Is the treatment failure in some patients caused by an insufficient AChE-inhibition [324] ?
Sleep and Inflammation
Whether considering cholinergic therapy or not, it would be beneficial to clarify which TBI patients have cholinergic dysfunction and how does it manifest itself. In rats, cortical glucose metabolism decreased only with bilateral BF lesions [325] -does this same apply to humans? As the EEG during REM-sleep is largely under cholinergic influence, could the REM-EEG analysis be used to reveal an eventual cholinergic dysfunction [23, 326] ? Or is the pattern of REM-EEG somehow connected with the clinical symptoms of TBI? The disturbed regulation of sleep after TBI may well be connected with a disturbance in the orexin system, which was found in > 90 % of patients after acute TBI [98, 327] . How does cholinergic stimulation affect sleep in TBIpatients? Further still, if the cholinergic dysfunction disturbs the normal sleep pattern, could this be in the background of long-term deterioration, which can be seen in a certain part of TBI victims [296, 328] ? In other words, could the disturbed REM-sleep lead to overstress in the brain leading thus to cognitive dysfunction or its exacerbation? Or is a deteriorating course connected to a chronic inflammatory reaction, which causes damage to BF neurons [310, 318, 329] ? Considering this possibility, the report that AChEinhibitors cause central anti-inflammatory effects is highly interesting [330] .
Rehabilitation
Studies of the cholinergic system offer some fascinating views also for TBI rehabilitation. As the cholinergic activity has been shown to be important for the long-term potentiation [29, 112] , and as human studies have suggested cholinergic stimulation to enhance learning and memory [70, 114] , could cholinergic facilitation improve the results of rehabilitation training? As recovery is considered to be a process of learning and plasticity, an increased cholinergic tone could well facilitate the formation of new connections and their consolidation. An intriguing possibility to carry out this facilitation e.g. during rehabilitation periods is vagal stimulation, which restores cognitive event-related potentials in BF lesioned animals correlating to ChAT restoration [331, 23] ? These prospects are not limited to the treatment of TBI but also for stroke rehabilitation. An important target for study is also the cholinergic effect on brain vasculature and oedema formation [203, 210] , which could well find clinical applications in both TBI and stroke -in the latter also possibly via the hypothermic effect of cholinergic stimulation [207] .
COLLECTING THE CLINICAL EVIDENCE OF CHOLINERGIC MODULATION IN TRAUMATIC BRAIN INJURY -SUGGESTIONS FOR FUTURE TRIALS
There are clearly two major areas that should be soon addressed in further clinical studies. First, as the accumulating evidence suggests significant clinical benefits for a notable section of chronic TBI patients, a conclusive evidence should be gathered with sufficiently large RCTs, as suggested already several times before. Second, as both the theoretical data [e.g. 29, [207] [208] [209] and clinical experience [259-261, own results] suggest that cholinergic facilitation or restoration in the early phase after trauma might have significant positive effects on the recovery process, a large multicenter trial with an AChE-inhibitor administered in the acute TBI should be carried out. We indeed have all signs of an eagerly awaited potential neuroprotective agent ready for human use, being perhaps closer to us than expected. The prerequisites for these kinds of studies merit some closer inspection.
Studies in Chronic Traumatic Brain Injury
As the accumulated experience has shown, there are some important aspects that have to be taken into account when planning a study of drug therapy in chronic TBI. These are listed in the Table 6 . The enormous variability of TBIs causes the main problem, since there is apparently a large diversity of neurochemical alterations in these patients [169] . Therefore, only a certain portion of patients is expected to respond, and there will probably be also patients with opposite effects. This causes a major problem in collecting evidence in RCTs. In fact, similar problems have been discussed also in AD studies [323, 332] . If we have a condition where only some patients respond to the treatment and we do not know how to select them, RCTs applied for all patients may be ineffective tools to show this benefit. This problem causes a requirement that the background variables should be registered in detail and extensively, in order to allow subgroup analyses. Thus, at least all demographic variables, injury details and imaging results should be included and if possible, also eventual pharmacogenomic variables such as ApoE genotype and CYP2D6 polymorphism [323] . Theoretically, depressive patients might respond less than others [333] , why some measure of depression should be included. Although the mechanisms behind cognitive deficits in the mildly injured patients may well be in many ways similar as in more severe injuries [e.g. 334] , it is probable that the variability in the causative factors of cognitive problems is even more pronounced in these patients, why their inclusion may diminish the power of the study. Of course, the cognitive problems of the postconcussional syndrome merit also treatment, but these should be studied in separate protocols including only mildly Repeated testing a few weeks after drug termination recommended, for eventual carry-over effect Possibility for the placebo arm to test active drug after study GCS = Glasgow Coma Scale, PTA = post-traumatic amnesia. injured patients. In order to avoid this variability in the patient material, it also necessary that the study includes only patients who have clearly reached the stable phase after the injury, which in practice means at least one year from the trauma. Moreover, the patients should not receive any other active treatments, pharmacological or other, during the trial in order to avoid confusing factors. Also patients who have other drugs possibly affecting the cholinergic system should be excluded. For example, the older antipsychotics diminish cholinergic activity [89] -might this be the reason why they are poorly tolerated in TBI patients [335] ?
A placebo-controlled study is a prerequisite when no earlier standard treatment exists. This demand is even more important in studies, where the treatment is supposed to affect the subjective well-being and cognitive functioning. Our unpublished results show that in cross-over protocol, most participants can recognize the active treatment from placebo. This causes an apparent problem for the blinding of results, and therefore parallel treatment protocols with the drug and placebo are recommended.
A major problem when studying treatment in TBI patients is the selection of outcome measures. Dealing with complicated and sophisticated cognitive and psychic functions is something wholly different from measuring blood pressure or cholesterol or following some clear endpoints such as stroke. This is another factor that increases the need for sufficient patient population, since natural variability in the outcome measures is larger than in many other settings. To minimize this problem, the outcome measures selected should be repeated several times both at baseline and during the maintenance dose. The TBI patients are especially problematic target group in this respect, since a pronounced variability of daily functioning is a typical feature of chronic TBI [336] [337] . Fatigue, poor sleeping, stress and motivation may easily cause marked daily fluctuations in cognitively demanding tasks. Thus, repeated testing to measure this normal fluctuation in order to separate eventual treatment effect from this background "noise" is essential.
The outcome measures should include reliably validated tests at least for divided and sustained attention, short-term memory, psychomotor speed, fatigue and global daily functioning. Attention, memory and speed are recommended to measure with modern well-validated computerized tests [338] [339] , which are also more rapid for the patient than conventional neuropsychological testing. Fatigue is recommended to be assessed both with the Fatigue Severity Scale [340] and the Modified Fatique Impact Scale [341] [342] . Sleep may be assessed e.g. with the Medical Outcome Study -Sleep Problems Measures [343] . Global daily functioning may be assessed with a variety of tools, such as Health Status Questionnaire (SF-36) [344] or Qolibri [345] .
As the drug tolerance may be highly variable and also the response dose-dependent in an unpredictable way, there is no sense to strive for maximal recommended dose, but instead use an individual approach. Starting with a minimum dose is important to avoid common gastrointestinal adverse effects, and thereafter the dose may be raised no sooner than every two weeks until some persisting adverse effects occur or until the patient feels satisfied with the dose. As TBI patients suffer from poor memory, lack of attention and poor stress tolerance, it is recommended that the achieved maintenance dose will not be continued for more than about one month. This is to avoid drop-outs, and the accumulated evidence shows that this period is surely sufficient to reveal the eventual response. During the trial, it is recommended to contact the patients regularly, in order to answer eventual problems of medication and facilitate compliance. Those who have been randomized to placebo should be offered a possibility to test the active drug after the randomization code has been broken. If possible, repeated testing with the outcome measures a few weeks after the study would be valuable to reveal the eventual carry-over, possibly helping to clarify if there is some common denominator for those showing the carry-over effect.
Studies in Acute Traumatic Brain Injury
As stated above, testing the effectiveness of cholinergic stimulation in the acute phase after trauma is strongly indicated. This kind of trial faces many different problems than met when studying chronic TBI. As the prognosis of TBI is highly variable, a large amount of randomized patients is required in order to find out a possible medication effect for recovery. In practice this means a multi-center study recruiting at least about 1000 patients. The study, should include only moderately or severely injured patients in order to avoid excessive variation. Data on demographic variables, injury mechanisms, eventual secondary injuries and imaging results should be collected. Preferably the imaging should be done with MRI during the acute phase, using all trauma-sensitive sequences fluid-attenuated inversion recovery (FLAIR), T2*-gradient echo and diffusionweighted imaging [346] . Determination of ApoE-genotype and CYP2D6 polymorphism are recommended, with the latter one depending on the AChE-inhibitor used (not needed for rivastigmine). The outcome measures should include the extended Glasgow Outcome Scale [347] , as well as computerized measures of attention and memory, as described above, and a global health measure.
The critical question in an acute setting trial is the dosing. How soon after injury should the treatment be started? If there is an initial cholinergic hyperactivity also in human TBI, could a drug-induced increase be detrimental [48, 318] ? On the other hand, animal studies suggest that this initial hyperactivity is very soon followed by hypoactivity [e.g. 190, [207] [208] . A pilot work studying the AChE activity in the ventricular cerebrospinal fluid in severe TBI is advisable in order to clarify whether there are signs of cholinergic hyperactivity during the first hours and days of human TBI. Without such knowledge, an educated guess of 24 hrs after the injury is recommended for starting point, but preferably the hypoactivity should be tried to be corrected as soon as it appears. At least comparable uncertainty concerns the duration of treatment, because here we have even less animal data for decision making. In rats, a single dose immediately after the trauma was effective [207] [208] . The AChE-inhibitor used may have significance, since those studies were done with rivastigmine, which causes pseudo-irreversible inhibition compared to donepezil and galantamine ( Table 5) . There are three alternatives that can be given reasons for: 1) as long as treated in hospital, 2) for one month or 3) till the outcome assessment. The first of these is much easier to carry out than the other alternatives.
The dose used is recommended to be kept fairly low based on current knowledge, although there is admittedly much uncertainty about this, too. If the patient material is sufficient, optimally the trial would include two different doses and a placebo. Otherwise 5 mg o.d. for donepezil, 4 mg b.i.d for galantamine and 1.5 mg b.i.d. for rivastigmine are recommended. The potential detrimental effects in acute treatment have to be followed closely, and it is suggested that in patients with any kind of deterioration in brain function during the trial, the study drug should be discontinued, irrespective of whether the deterioration is suspected to be caused by the drug or not. An important issue to analyze after breaking the randomization code is whether these interruptions were more frequent in the active of placebo arms. In order to monitor the clinical state sufficiently, a daily registration of GCS as well as short and simple measures of attention and memory should be applied as long as treated in the hospital. The duration of PTA is an important measure to follow, and doing this with the Galveston Orientation and Amnesia test [348] would serve also as a sufficient measure of cognition. Other important variables to register are the duration of intensive care and hospital care. The outcome measures could be assessed six months after the injury, which is normally a sufficient time for all acute problems to subside.
CONCLUSION
As discussed in this review, there exists large and impressive data suggesting a crucial role for cholinergic innervation in human TBI. This does by no means rule out that other both monoaminergic and peptidergic neurotransmitters may also have important roles. However, the cholinergic system seems to be intimately involved in many central pathophysiological processes of TBI, both at the level of brain injury and repair and higher brain function. In addition, there are several convergent pieces of evidence supporting the view that cholinergic stimulation may be beneficial to prohibit or normalize the consequences of these processes.
Clinical experience has quite clearly shown that some patients with chronic TBI may show a substantial improvement with AChE-inhibitors. An urgent challenge is to confirm this in well-conducted RCTs, and to seek whether there are ways to find the responders on the basis of some clinical characteristics or measurable features. Even more fascinating is the scene that in AChE-inhibitors, we may have potent neuroprotective or repair-enhancing agents available closer than expected. Whether these substances given acutely after TBI hasten the recovery or lead to improved outcome is of topmost interest and if proven, would mean a major breakthrough in clinical neuroscience. It is very regrettable but understandable that drug companies are reluctant to carry out costly studies for new indications if the patent guard is ending in the near future. If so, I consider that based on the various arguments discussed in this review, the medical community should take the responsibility and carry out the proposed studies. Carrying out them could well be also the interest of insurance companies, since already rescuing some young persons from retirement to productive members of society would cover the costs, not to speak of future savings.
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